Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~The following inclusion criteria had to be present at BL 1 (Screening visit prior to transplantation):~1. Males or females, aged 18 - 65 years~2. Recipients of de novo cadaveric, living unrelated or living related kidney transplants~3. Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at BL 1, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility~4. Patients who are willing and able to participate in the study and from whom written informed consent has been obtained~   Of all patients included into the study at BL 1 (prior to transplantation), those who continued into the randomized study period had to meet the following condition at BL 2, prior to randomization:~5. Patients had to be on an immunosuppressive regimen with EC-MPS (target dose; 1440 mg/day, if tolerated; minimal dose: 720 mg/day), cyclosporine and corticosteroids~6. Patients with an actual serum creatinine =\< 3.0 mg/dl~Exclusion Criteria:~The following exclusion criteria must not be present at BL 1 (Screening visit prior to transplantation):~1. More than one previous renal transplantation~2. Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney~3. Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation)~4. Patients who are recipients of A-B-O incompatible transplants~5. Patients with a historical or current peak PRA of \> 25%~6. Patients with already existing antibodies against the HLA-type of the receiving transplant~7. Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception~   Of all patients included into the study at BL 1 (prior to transplantation), those who met one or more of the following criteria at BL 2, prior to randomization, should not continue into the randomized study period:~8. Graft loss or death~9. Changes to the immunosuppressive regimen prior to randomization due to immunologic reasons~10. Patients who suffered from severe rejection (\>= BANFF II acute rejection), recurrent acute rejection, or steroid resistant acute rejection~11. Proteinuria \> 1g/day~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus + Mycophenolate sodium (Type: EXPERIMENTAL): Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5 mg prednisolone or equivalent and had to be continued throughout the first year. Cyclosporine withdrawal started from Month 4.5 post-transplant.
- Cyclosporine + Mycophenolate sodium (Type: ACTIVE_COMPARATOR): Cyclosporine tablets orally twice a day to achieve protocol specific target levels and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.

Based on this trial design, predict the completion outcome and termination type (if applicable).